Allogeneic transplantation for the elderly patient with acute myelogenous leukemia or myelodysplastic syndrome

Seminars in Hematology
M de Lima, S Giralt

Abstract

Acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) are diseases of the elderly. Allogeneic hematopoietic stem cell transplantation (HSCT) offers the possibility of cure for these malignancies, but until recently its use was restricted to younger patients due to prohibitive treatment-related mortality. Improvements in supportive care and development of reduced-intensity preparative regimens have allowed patients in the sixth, seventh, and to a lesser extent, eighth decade of life to be treated with allogeneic transplantation. Major obstacles to extending this form of treatment to older patients are lack of promptly available donors, graft-versus-host disease (GVHD), delayed immune recovery, and the high prevalence of refractory and relapsed disease intrinsic to the natural history of these myeloid malignancies. Here we review current results of allogeneic blood and marrow transplantation for AML and MDS in the elderly.

References

Nov 28, 2001·Hematology·F R AppelbaumJ E Dick
Aug 27, 2002·Annual Review of Genomics and Human Genetics·Louise M Kelly, D Gary Gilliland
Apr 17, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hartmut BertzJürgen Finke
Oct 18, 2003·Critical Reviews in Oncology/hematology·John E Godwin, Scott E Smith
Dec 4, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Issa F KhouriRichard E Champlin
Mar 3, 2004·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Daniel R CourielRichard Champlin
Dec 31, 2004·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Bart L ScottH Joachim Deeg
Jan 22, 2005·Annual Review of Medicine·Youngji Park, Stanton L Gerson
Feb 25, 2005·American Journal of Public Health·Walter M Bortz
Mar 5, 2005·Blood·Mohamed SorrorRainer Storb
Mar 19, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Frédéric BaronRainer Storb
Apr 13, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Herschel WallenAjay K Gopal
Jun 22, 2005·Proceedings of the National Academy of Sciences of the United States of America·Derrick J RossiIrving L Weissman
Jul 5, 2005·Bone Marrow Transplantation·J AlamoS A Giralt
Jul 13, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Koen van BesienW Stock
Aug 3, 2005·Current Opinion in Immunology·Amir A Sadighi Akha, Richard A Miller
Aug 9, 2005·Current Opinion in Immunology·Christian R GomezElizabeth J Kovacs
Aug 16, 2005·Current Opinion in Immunology·Jörg J Goronzy, Cornelia M Weyand

❮ Previous
Next ❯

Citations

Dec 7, 2011·Archivum Immunologiae Et Therapiae Experimentalis·H Joachim Deeg, Matthias Bartenstein
Feb 22, 2008·Proceedings of the National Academy of Sciences of the United States of America·A Mario MarcondesH Joachim Deeg
May 20, 2014·Journal of Geriatric Oncology·Holly M HolmesSupriya G Mohile
Jun 20, 2007·Leukemia & Lymphoma·C StruppU Germing
Sep 29, 2011·Seminars in Oncology·Simrit ParmarRichard Champlin
Jan 9, 2008·Seminars in Hematology·A John Barrett, Bipin N Savani
Oct 9, 2007·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·S S TanW E Fibbe
Feb 4, 2014·Journal of Geriatric Oncology·Haifa Kathrin Al-AliDietger Niederwieser
Oct 23, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Christine N DuncanLewis B Silverman
Mar 7, 2007·Expert Review of Anticancer Therapy·Gail J Roboz
Apr 4, 2013·Expert Review of Hematology·Mehmet A ÖzcanZafer Gülbas

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.